[ Diabetes Type 2 ]

Relationships Between Metabolic Syndrome and Other Baseline Factors and the Efficacy of Ezetimibe/Simvastatin and Atorvastatin

To evaluate the protective effect of tannins from Ficus racemosa (F. DESIGN: Prospective cohort study. The available data suggest that the target cholesterol concentration in patients with diabetes should be similar to that in non-diabetic individuals with a previous myocardial infarction. Synopsis: Seven comorbid major diseases (diabetes mellitus type II [DM], hypertension [HTN], coronary artery disease [CAD], hypercholesterolemia [Hch], cerebrovascular disease [CVD], chronic kidney disease [CKD], and anemia) were examined. We used small mesenteric arteries from control, diabetic (streptozotocin-induced), apolipoprotein-E-deficient (ApoE-/-), and diabetic ApoE-/- mice. People with less education were more likely to exhibit lower sensitivity to HTN and hypercholesterolemia, and people living in rural areas were less sensitive to DM and hypercholesterolemia.Caution is needed in interpreting the results of community studies using self-reported data on chronic diseases, especially hypercholesterolemia, among adults aged 50 years and older. Adiposity and ischemic and hemorrhagic stroke: prospective study in women and meta-analysis [published online Sept.

The presence of predictive factors should be considered in planning lipid-altering therapy. Treatment response to statins can vary in patients with type 2 diabetes, attributed to various patient-related characteristics, including demographic and metabolic factors, baseline lipid levels, genetic polymorphisms, and the metabolic syndrome (MetS) (1–6). This analysis explored relationships between various baseline characteristics and changes in lipids and high-sensitivity C-reactive protein (hs-CRP) in the presence/absence of MetS in the Vytorin versus Atorvastatin in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia (VYTAL) study (7). Further studies are required in order to clarify the potential diabetogenic effects of statins in these high risk populations. We excluded ISSNHL patients who had been treated with intratympanic injection of steroid because of the limited case number; we had not provided intratympanic injection of steroid as one of the treatments for patients with ISSNHL before April 2013.

Tags: , ,